Introduction/Background To report our single-center experience of the Da Vinci robotic surgery system in the management of endometrial cancer (EC) patients at the Department of Obstetrics and Gynecology, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia, during 2019–2022.

Methodology We descriptively summarized the preoperative, intraoperative, and postoperative outcomes. Moreover, we conducted subgroup analyses based on obesity (BMI ≥30 kg/m2) and the intraoperative use of indocyanine green dye (ICG).

Results Overall, 81 patients were analyzed. Sixty-seven patients (82.7%) were obese. The mean operative time and estimated blood loss (EBL) were 247.22±74.42 min and 100.86±71.82 ml, respectively. The mean number of retrieved pelvic LNs was 3±3.17 (range: 0–15). The use of IGD was employed in 40 patients (49.4%). Only single patient (1.2%) underwent conversion to laparotomy. Besides, only three patients (3.7%) experienced vaginal laceration intraoperatively. The mean hospital stay was 1.37±0.73 days. No patient experienced postoperative complications. Most tumors had endometrioid histology (81.5%), grade-1 tumor (49.4%), and stage-1A disease (67.9%). At 3-year follow-up, only two patients (2.5%) developed recurrence. Patients who received the IGD had significantly lower operative time, lower EBL, and lower hospital stay compared with patients who did not receive it. However, there was no significant difference between both groups regarding the number of retrieved pelvic LNs.

Conclusion Robotic surgery was technically feasible and safe. The use of ICG was linked to favorable outcomes, in terms of decreased operative time, EBL, and hospital stay. Obesity did not impact the perioperative surgical outcomes.

Disclosures None